RxDoctor Payments Data

Diana Cholakian Pearre, MD

Gynecologic Oncology · Burbank, CANPI 1659714475

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by AbbVie at 53.7% of the total. 2025 is the largest year on record at $3,096, more than ten times the $49 reported in 2019.

$4,422in general payments, 2019–2025

Across 77 payments — averaging $57.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Intuitive Surgical$556
  • Astellas Pharma US Inc$276
  • Sumitomo Pharma America, Inc.$273
  • Myriad Genetic Laboratories, Inc.$121
  • Caris MPI, Inc.$104
  • plus $716 from 20 others
$40,000in research payments, 2019–2025

Across 1 payment — averaging $40,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genmab U.S., Inc.$40K

What the payments were for

  • Consulting fees$1,95044%
  • Travel & lodging$2385%
  • Food & beverage$2,04046%
  • Education$1944%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,422 in reported general payments places this provider in the 65th percentile of 152 gynecologic oncology providers in California.

See all gynecologic oncology providers in California

Medicare billing

Part B allowed, 2024
$61,627
Medicare patients
157
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol30$1,586
Fluconazole14$118
Triamcinolone Acetonide28$88
Ibuprofen24$56
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$48
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$38

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →